Evaluating the use of dexmedetomidine for the reduction of delirium: An integrative review.
Heart Lung
; 47(6): 591-601, 2018 11.
Article
en En
| MEDLINE
| ID: mdl-30266265
ABSTRACT
Delirium, an acute change in cognition and attention not secondary to a pre-existing condition or dementia, affects nearly 40,000 hospitalized older adults in the United States every day. Delirium is associated with increased healthcare costs of $16,303 to $64,421 per patient. To date, no single pharmacological intervention is effective in preventing or treating delirium in critically ill patients. Evidence suggests the alpha-2 agonist, dexmedetomidine, may reduce or prevent delirium. An integrative review examined whether dexmedetomidine was associated with a lower incidence of delirium compared to other analgesic and sedation strategies. PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guided this review and 16 publications met quality criteria for inclusion. These studies support that postoperative administration of dexmedetomidine may reduce delirium in patients, particularly following cardiac surgery. Further research is needed to determine the benefits of dexmedetomidine in patients on mechanical ventilation and optimal timing and duration of administration.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Contexto en salud:
1_ASSA2030
/
6_ODS3_enfermedades_notrasmisibles
Problema de salud:
1_doencas_nao_transmissiveis
/
6_mental_health_behavioral_disorders
Asunto principal:
Dexmedetomidina
/
Delirio
/
Agonistas de Receptores Adrenérgicos alfa 2
/
Hipnóticos y Sedantes
Tipo de estudio:
Etiology_studies
/
Systematic_reviews
Límite:
Humans
Idioma:
En
Revista:
Heart Lung
Año:
2018
Tipo del documento:
Article